Clearance of [125I]-tumor necrosis factor-α from the brain into the blood after intracerebroventricular injection in rats

NeuroImmunoModulation

Volumn 5, Issue 5, 1998, Pages 261-269

  Chen, Guanjie ^a   Reichlin, Seymour ^a,b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Brain; Cytokine; Tumor necrosis factor alpha

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA; LIPOPOLYSACCHARIDE; RADIOACTIVE IODINE;

ACUTE PHASE RESPONSE; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFECT; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; LATERAL BRAIN VENTRICLE; METABOLIC ACTIVATION; NONHUMAN; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; RAT; SUPERIOR SAGITTAL SINUS; ANIMAL; BRAIN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLIC CLEARANCE RATE; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; INJECTIONS, INTRAVENOUS; INJECTIONS, INTRAVENTRICULAR; IODINE RADIOISOTOPES; LIPOPOLYSACCHARIDES; MALE; METABOLIC CLEARANCE RATE; RATS; RATS, SPRAGUE-DAWLEY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031595690     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026346     Document Type: Article

References (59)

1. Kossmann T, Hans VH, Imhof HG, Stocker R, Grob P, Trentz O, Morganti-Kossman C: Intrathecal and serum interleukin-6 and the acute-phase response in patients with severe traumatic brain injuries. Shock 1995;4:311-317.
2. McClain C, Cohen D, Phillips R, Ott L, Young B: Increased plasma and ventricular fluid interleukin-6 levels in patients with head injury. J Lab Clin Med 1991;118:225-231.
3. Shohami E, Novikov M, Bass R, Yamin A, Gallily R: Closed head injury triggers early production of TNF alpha and IL-6 by brain tissue. J Cereb Blood Flow Metab 1994;14:615-619.
4. Quattrocchi KB, Frank EH, Miller CH, Dull ST, Howard RR, Wagner FC Jr: Severe head injury: Effect upon cellular immune function. Neurol Res 1991;13:13-20.
5. Goodman JC, Robertson CS, Grossman RG, Narayan RK: Elevation of tumor necrosis factor in head injury. J Neuroimmunol 1990;30: 213-217.
6. Beamer NB, Coull BM, Clark WM, Hazel JS, Silberger JR: Interleukin 6 and interleukin 1 receptor antagonist in acute stroke. Ann Neurol 1995;37:800-805.
7. Amado JA, Lopez-Espadas F, Vazquez-Barquero A, Salas E, Riancho JA, Lopez-Cordovilla JJ, Garcia-Unzueta MT: Blood levels of cytokines in brain dead patients. Relationship with circulating hormones and acute phase reactants. Metabolism 1995;44:812-816.
8. De Simone MG, Sironi M, De Luigi A, Manfridi A, Mantovani A, Ghezzi P: Intracerebroventricular injection of interleukin 1 induces high circulating levels of interleukin 6. J Exp Med 1990;171:1773-1778.
9. De Simoni MG, De Luigi A, Gemma L, Sironi M, Manfridi A, Ghezzi P: Modulation of systemic interleukin-6 induction by central interleukin-1.Am J Physiol 1993;265:R739-R742.
10. Romero LI, Kakucska I, Lechan RM, Reichlin S: Interleukin-6 (IL-6) is secreted from the brain after intracerebroventricular injection of IL-1β in rats. Am J Physiol 1996;270:R518-R524.
11. 125I-labelled interleukin-6 from brain into blood following intracerebroventricular injection in rats. Endocrinology 1997;138: 4830-4836.
12. Xiao E, Xia L, Ferin M, Wardlaw SL: Intracerebroventricular injection of interleukin-1 stimulates the release of high levels of interleukin-6 into peripheral blood in the monkey (abstract P3-292). Program 79th Annual Meeting. Minneapolis, The Endocrine Society, 1997, p 509.
13. Gottschall PE, Komaki G, Arimura A: Increased circulating interleukin-1 and interleukin-6 after intracerebroventricular injection of lipopolysaccharide. Neuroendocrinology 1992; 56:935-938.
14. De Simoni MG, Del Bo R, De Luigi A, Simard S, Forloni G: Central endotoxin induces different patterns of interleukin (IL)-1β and IL-6 messenger ribonucleic acid expression and IL-6 secretion in the brain and periphery. Endocrinology 1995;136:897-902.
15. Roth J, Conn CA, Kluger MJ, Zeisberger E: Kinetics of systemic and intrahypothalamic IL-6 and tumor necrosis factor during endotoxin fever in guinea pigs. Am J Physiol 1993;265: R653-R658.
16. Robertson CS: Inflammatory cells and the hypermetabolism of head injury. J Lab Clin Med 1991;118:205.
17. Robertson CS, Goodman JC, Grossman RG: Blood flow and metabolic therapy in CNS injury. J Neurotrauma 1992;9:(suppl 2):S579-S594.
18. Turchik JB, Bornstein DL: Role of the central nervous system in acute-phase responses to leukocytic pyrogen. Infect Immun 1980;30:439-444.
19. Bodnar RJ, Pasternak GW, Mann PE, Paul D, Warren R, Donner DB: Mediation of anorexia by human recombinant tumor necrosis factor through a peripheral action in the rat. Cancer Res 1989;49:6280-6284.
20. Kakucska I, Qi Y, Clark BD, Lechan RM: Endotoxin-induced corticotropin-releasing hormone gene expression in the hypothalamic paraventricular nucleus is mediated centrally by interleukin-1. Endocrinology 1993;133: 815-821.
21. Benveniste EN: Inflammatory cytokines within the central nervous system: Sources, function, and mechanism of action. Am J Physiol 1992; 263:C1-C16.
22. Faggioni R, Benigni F, Ghezzi P: Proinflammatory cytokines as pathogenetic mediators in the central nervous system. Neuroimmuno-modulation 1995;2:2-15.
23. Gatti S, Bartfai T: Induction of tumor necrosis factor-alpha mRNA in the brain after peripheral endotoxin treatment: Comparison with interleukin-1 family and interleukin-6. Brain Res 1993;624:291-294.
24. Hopkins SJ, Rothwell NJ: Cytokines and the nervous system. I. Expression and recognition. Trends Neurosci 1995;18:83-88.
25. McGeer PL, McGeer EG: The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative disease. Brain Res Rev 1995;21:195-218.
26. Schöbitz B, De Kloet ER, Holsboer F: Gene expression and function of interleukin 1, interleukin 6 and tumor necrosis factor in the brain. Prog Neurobiol 1994;44:397-432.
27. Eskandart MK, Nguyen DT, Kunkel SL, Remick DG: WEHI 164 subclone 13 assay for TNF: Sensitivity, specificity and reliability. Immunol Invest 1990;19:69-79.
28. Lantz RC, Parliman G, Chen GJ, Carter DE: Effect of arsenic exposure on alveolar macrophage function. 1. Effect of soluble As(III) and AS(V). Environ Res 1994;67:183-195.
29. Bradbury MW, Cserr HF, Westrop RJ: Drainage of cerebral interstitial fluid into deep cervical lymph of the rabbit. Am J Physiol 1981; 240:F329-F336.
30. Szentistvanyi I, Patlak CS, Ellis RA: Drainage of interstitial fluid from different regions of rat brain. Am J Physiol 1984;246:F835-F844.
31. Yamada S, DePasquale M, Patlak CS, Cserr HF: Albumin outflow into deep cervical lymph from different regions of rabbit brain. Am J Physiol 1991;261:H1197-H1204.
32. Ichimura T, Fraser PA, Cserr HF: Distribution of extracellular tracers in perivascular spaces of the rat brain. Brain Res 1991;545:103-113.
33. 14C]inulin after intrathecal injection. Brain Res 1973; 52:323-332.
34. Cserr H: Potassium exchange between cerebrospinal fluid, plasma and brain. Am J Physiol 1965;209:1219-1226.
35. Kawakami J, Yamamoto K, Sawada Y, Iga T: Prediction of brain delivery of ofloxacin, a new quinolone, in the human from animal data. J Pharmacokinet Biopharm 1994;22:207-227.
36. Chung S-J, Ramanathan VK, Brett CM, Giacomini KM: Saturable disposition of taurine in the rat cerebrospinal fluid. J Pharmacol Exp Ther 1996;276:676-682.
37. Banks WA, Kastin AJ, Gutierrez EG: Penetration of interleukin-6 across the murine bloodbrain barrier. Neurosci Lett 1994;179:53-56.
38. Banks WA, Kastin AJ, Broadwell RD: Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation 1995;2:241-248.
39. Cserr HF, Harling-Berg CJ, Knopf PM: Drainage of brain extracellular fluid into blood and deep cervical lymph and its immunological significance. Brain Pathol 1992;2:269-276.
40. Knopf PM, Cserr HF, Nolan SC, Wu T-Y, Harling-Berg CJ: Physiology and immunology of lymphatic drainage of interstitial and cerebrospinal fluid from the brain. Neuropathol Appl Neurobiol 1995;21:175-180.
41. Cserr HF, Knopf PM: Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: A new view. Immunol Today 1992;13:507-512.
42. Cserr HF, DePasquale M, Harling-Berg CJ, Park JT, Knopf PM: Afferent and efferent arms of the humoral immune response to CSF-administered albumins in a rat model with normal blood-brain barrier permeability. J Neuroimmunol 1992;41:195-202.
43. Gordon LB, Knopf PM, Cserr HF: Ovalbumin is more immunogenic when introduced into brain or cerebrospinal fluid than into extracerebral sites. J Neuroimmunol 1992;40:81-88.
44. Andersson P-B, Perry VH, Gordon S: Intracerebral injection of proinflammatory cytokines or leukocyte chemotaxins induces minimal myelomonocytic cell recruitment to the parenchyma of the central nervous system. J Exp Med 1992;176:255-259.
45. Lieberman AP, Pitha PM, Shin HS, Shin ML: Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. Proc Natl Acad Sci 1989;86:6348-6352.
46. Romero LI, Schettini G, Lechan RM, Dinarello CA, Reichlin S: Bacterial lipopolysaccharide induction of IL-6 in rat telencephalic cells is mediated in part by IL-1. Neuroendocrinology 1993;57:892-897.
47. Lechan RM, Toni R, Clark BD, Cannon JG, Shaw AR, Dinarello CA, Reichlin S: Immunoreactive interleukin-1 beta localization in the rat forebrain. Brain Res 1990;514:135-140.
48. Ringheim GE, Burgher KL, Heroux JA: Interleukin-6 mRNA expression by cortical neurons in culture: Evidence for neuronal sources of interleukin-6 production in the brain. J Neuroimmunol 1995;63:113-123.
49. Breder CD, Hazuka C, Ghayur T, Klug C, Huginin M, Yasuda K, Teng M, Saper CB: Regional induction of tumor necrosis factor-α expression in the mouse brain after systemic lipopolysaccharide administration. Proc Natl Acad Sci USA 1994;91:11393-11397.
50. Tarkowski E, Rosengren L, Blomstrand C, Wikkelso C, Jensen C, Ekholm S, Tarkowski A: Early intrathecal production of interleukin-6 predicts the size of brain lesions in stroke. Stroke 1995;26:1393-1398.
51. Gijbels K, Van Damme J, Proost P, Put W, Carton H, Billiau A: Interleukin 6 production in the central nervous system during experimental autoimmune encephalomyelitis. Eur J Immunol 1990;20:233-235.
52. r 55,000 protein). Cancer Res 1992;52:1123-1128.
53. Faggioni R, Fantuzzi G, Villa P, Buurman W, Tits LJH van, Ghezzi P: Independent down-regulation of central and peripheral tumor necrosis factor production as a result of lipopolysaccharide tolerance in mice. Infect Immun 1995;63:1473-1477.
54. Reichlin S: Alternative pathways of neural control of the immune process. Ann NY Acad Sci 1998;840:301-316.
55. Huang QH, Takaki A, Arimura A: Central nor-adrenergic system modulates plasma interleukin-6 production by peripheral interleukin-1. Am J Physiol 1997;273:R731-R738.
56. Hori T, Katafuchi T, Take S, Shimizu N, Niijima A: The autonomie nervous system as a communication channel between the brain and the immune system. Neuroimmunomodulation 1995;2:203-215.
57. Tracey KJ, Morgello S, Koplin B, Fahey TJ III, Fox J, Aledo A: Metabolic effects of cachectin/ tumor necrosis factor are modified by site of production. J Clin Invest 1990;86:2014-2024.
58. Weller M, Fontana A: Failure of current immunotherapy for malignant glioma. Tumor derived TGF-β, T-cell apoptosis, and the immune privilege of the brain. Brain Res Rev 1995;21: 128-151.
59. Zlokovic BV: Cerebrovascular permeability to peptides: Manipulations of transport systems at the blood-brain barrier. Pharm Res 1995;12: 1395-1406.